Management of Dupuytren's disease--clear advice for an elusive condition
about
First identification of resident and circulating fibrocytes in Dupuytren's disease shown to be inhibited by serum amyloid P and XiapexDupuytren's contracture: a retrospective database analysis to determine hospitalizations in the NetherlandsRecapitulation of fibromatosis nodule by multipotential stem cells in immunodeficient miceIn vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related propertiesThe emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's diseaseAggressive Dupuytren's diathesis in a young woman.Upper limb musculoskeletal abnormalities in type 2 diabetic patients in low socioeconomic strata in PakistanSplinting after contracture release for Dupuytren's contracture (SCoRD): protocol of a pragmatic, multi-centre, randomized controlled trial.Clinical effectiveness of post-operative splinting after surgical release of Dupuytren's contracture: a systematic review.Night-time splinting after fasciectomy or dermo-fasciectomy for Dupuytren's contracture: a pragmatic, multi-centre, randomised controlled trial.Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy.Recent Surgical and Medical Advances in the Treatment of Dupuytren's Disease - A Systematic Review of the LiteratureDupuytren's: a systems biology disease.Revised Tubiana's staging system for assessment of disease severity in Dupuytren's disease-preliminary clinical findings.A diabetic patient presenting with stiff hand following fasciectomy for Dupuytren's contracture: A case report.Assessment of clinical severity in Dupuytren's disease.Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiologyDifferential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue.Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances.Embryonic Stem Cell-like Population in Dupuytren's Disease.Treatment of dupuytren disease with injectable collagenase in a veteran population: a case series at the department of veterans affairs new jersey health care system.Dupuytren's disease presentation, referral pathways and resource utilisation in Europe: regional analysis of a surgeon survey and patient chart review.Radiotherapy in fascial fibromatosis: a case series, literature review and considerations for treatment of early-stage disease.Dupuytren's disease therapy: targeting the vicious cycle of myofibroblasts?Dupuytren Disease: Is There Enough Comprehensive Patient Information on the Internet?Dupuytren's Contracture: A Bibliometric Study of the Most Cited Papers.Embryonic Stem Cell-Like Population in Dupuytren's Disease Expresses Components of the Renin-Angiotensin System.Postoperative management of Dupuytren's disease with topical nitroglycerin.Understanding Dupuytren's Disease Using Systems Biology: A Move Away from Reductionism.Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with anT2 signal intensity as an imaging biomarker for patients with superficial Fibromatoses of the hands (Dupuytren's disease) and feet (Ledderhose disease) undergoing definitive electron beam irradiation.What do we know about managing Dupuytren's disease cost-effectively?The contribution of HLA molecules to Dupuytren's contracture in a Southeast Brazilian population.Safety and Effectiveness of Percutaneous Needle Fasciotomy for Dupuytren's Disease in the Palm.
P2860
Q21132009-E206AA4C-1FBA-4D78-82DD-EE5081FA94B4Q21199594-D84992EB-62E8-442B-8B20-C5E5C4AF0123Q28476721-9C176CE0-FB17-4A39-A5F1-D2C38B555CE7Q28481259-01A8429C-A799-436F-99D6-38AA44AB2F56Q34153159-8C483A40-8173-4834-BBAE-71C448464FA1Q34389581-5E8AA44C-7779-45B7-9781-72C6D5FB38CDQ34527335-A332513E-E2FF-4E34-9C82-6A020AE29F3CQ34552657-E92BB917-9DDB-4551-BD87-9E90496AB59BQ34775076-8A60EC4D-2202-4C06-953A-8D981C94925AQ34798640-39EB5CDF-B167-4307-988E-87D6F8FDA255Q35137482-C8AE75F5-1D2E-47E9-A96B-91A720FE9D82Q35760121-C7865332-65AE-478C-B9AF-CB2C6CE1AF2EQ35800728-F0243106-B2F3-4E1B-BA42-D3ACCD5BD828Q35840713-DF9AEF93-35D6-45E6-9813-E5C7C8260E51Q36861989-36A9B7FC-9929-4CB9-BE33-23A1626266FAQ36969975-00004A27-3BAF-4888-A5D2-332F38AE77D4Q37035099-B4758B17-DCCE-4AE9-A23E-DD8B8F7C8A05Q37299489-6AE26D7E-A0D4-474B-9512-A553510DDCA4Q37299495-F95E689F-C2C0-4844-9F03-39CA49C9B0BAQ37300243-420A6685-569F-43FA-BCDC-71CD13351D28Q37481424-95707703-D2FC-451A-952D-4D7B3A2AE6DFQ37688223-1B1ED870-7B88-44D2-B1EB-D0104469D1D2Q38081467-63BC7EE2-4196-4A97-BA23-4264CAFF4826Q38204474-EA1B4311-18FE-4686-86B7-8A08AF7C21D3Q38675433-6EE50FC8-4AA5-4DDA-BCFD-58AD7E1DF8D0Q38713150-422B3669-066A-42B2-BC5C-E8383B3BA4B2Q40521021-5756508E-3F36-4A9F-A7A7-0F755774A74CQ41306540-0DF9BCFC-48BD-4A33-B625-48BE25AF119DQ41858908-2DC30EEF-8D0D-4D64-8623-DE6E17A42BF1Q42321526-66BA9A4F-3805-445B-98F8-B6374366665AQ47103542-956B1D7C-88D0-4B65-B7A8-BC668A19796FQ47594513-5E6B8EA4-FD58-4C39-BCF4-A8A5BE0E781DQ47711682-81B4BEF0-6B47-489C-A2DF-163EDB376B1BQ48859443-750CBF94-3170-4E85-A063-0B79402BCEBAQ50185516-C163E23C-026F-41C5-9876-5762AA3552A5
P2860
Management of Dupuytren's disease--clear advice for an elusive condition
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Management of Dupuytren's disease--clear advice for an elusive condition
@ast
Management of Dupuytren's disease--clear advice for an elusive condition
@en
type
label
Management of Dupuytren's disease--clear advice for an elusive condition
@ast
Management of Dupuytren's disease--clear advice for an elusive condition
@en
prefLabel
Management of Dupuytren's disease--clear advice for an elusive condition
@ast
Management of Dupuytren's disease--clear advice for an elusive condition
@en
P2860
P356
P1476
Management of Dupuytren's disease--clear advice for an elusive condition
@en
P2093
D A McGrouther
P2860
P356
10.1308/003588406X83104
P577
2006-01-01T00:00:00Z